http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
최보경 ( Bo Kyung Choi ),이희선 ( Hee Sun Lee ),황인혜 ( In Hye Hwang ),신경화 ( Kyung Hwa Shin ),최문기 ( Mun Ki Choi ),최보광 ( Bo Gwang Choi ),안강희 ( Kang Hee Ahn ),남형석 ( Hyung Seok Nam ),황종민 ( Jong Min Hwang ),성은영 ( 대한내과학회 2010 대한내과학회지 Vol.79 No.4
목적: 만성 신질환 환자에서 세포성 면역기능이 감소되어 결핵에 이환될 위험성이 높으며, 특히 폐외결핵의 발생 빈도가 높은 것으로 알려져 있다. 이에 신기능에 따른 폐외결핵의 임상양상, 치료 반응, 질환과 연관된 사망률의 차이점을 비교하였다. 방법: 2003년 1월부터 2007년 12월까지 폐외결핵으로 진단된 18세 이상의 환자를 대상으로 하였고, 진단 당시의 크레아티닌 값을 이용하여 MDRD 공식으로 계산한 추정 사구체 여과율(eGFR)이 60 mL/min/1.73 m2을 기준으로 신기능 장애군(Group I)과 정상 신기능군(Group II)으로 분류하여 폐외결핵의 임상상, 치료성공률, 사망률 및 치료기간의 차이를 후향적 비교 분석하였다. 결과: 총 342명의 환자 중 Group I은 30명으로 이중 투석을 시행하고 있는 환자는 6명이었고, Group II는 312명으로, 각각의 평균 사구체 여과율은 34±19 mL/min/1.73 m2, 102±26 mL/min/1.73 m2이었다. Group I에서 고연령, 빈혈, 저알부민증이 많았으며, 고혈압, 당뇨병 및 심혈관계 질환을 동반한 경우가 많았다. 폐외결핵의 발생 부위는 두 환자군 모두 (Group I vs. Group II)에서 흉막(30.0% vs. 28.2%)이 가장 빈도가 높았고, 신경계통(23.3% vs. 16.3%)과 림프절(16.7% vs. 17.6%)의 감염이 흔하였으나, 통계학적 유의성은 없었다 (p=0.379). 모든 환자들은 표준 결핵화학요법인 HERZ, HER 및 HRZ 등을 용량 조절하여 치료하였으며, 두 환자군 모두에서 치료 실패 및 재발은 없었다. 결핵과 연관된 사망률은 Group I에서 높았으며(Group I, 22.2% vs. Group II, 2.8%, p<0.001), 연령, 혈색소 및 알부민, 당뇨병, 고혈압 및 심혈관계 질환의 유무를 보정하였을 경우에도 Group I이 사망의 위험률이 높았다(HR=11.51, 95%CI 2.512~52.741; p=0.002). 치료 중 이탈된 환자 및 사망환자를 제외하였을 경우, Group I이 치료 기간이 짧았다(278±110일 vs. 367±170일, p=0.009). 결론: 신기능 장애 환자에서 폐외결핵에 대한 치료기간이 연장되지 않았고 사망을 제외한 치료실패와 재발이 없었으나 폐외결핵으로 인한 사망률은 높았고, 신기능 저하 자체가 사망의 독립적인 위험 요소였다. 그러므로 신기능 장애 환자에서 폐외결핵에 대한 적극적인 진단 및 치료가 더 요구된다고 판단한다. Background/Aims: There is an increased risk of tuberculosis (TB) with impaired cellular immunity and extrapulmonary TB is more common in patients with chronic kidney disease. We explored the clinical features and treatment outcomes of extrapulmonary TB according to renal function. Methods: This retrospective study reviewed the medical records of patients diagnosed with extrapulmonary TB between January 2003 and December 2007. We classified the patients into two groups using the glomerular filtration rate (eGFR), estimated using the Modification of Diet in Renal Disease (MDRD) formula cut-off of 60 mL/min/1.73 m2 and evaluated their clinical features, treatment outcome and mortality (Group I vs. Group II, ≥ 60 mL/min/1.73 m2). Results: The mean eGFR of Groups I (n=30) and II (n=312) was 34±19 and 102±26 mL/min/1.73 m2, respectively. The pleura was the most frequent site of TB in both groups (Group I, 30.0% vs. Group II, 28.2%; p=0.379). There was no treatment failure or recurrence in either group. The mortality was higher in Group I (22.2% vs. 2.8%; p<0.01). In a multivariate analysis, eGFR<60 mL/min/1.73 m2 was an independent risk factor for mortality (HR=11.51, CI 2.512-52.741; p=0.002). Conclusions: Mortality related to extrapulmonary TB was higher in patients with impaired kidney function and kidney function was an independent predictor. However, there was no difference in treatment failure and recurrence according to renal function. (Korean J Med 79:387-393, 2010)
점막하종양 형태를 보인 Mucosa-associated Lymphoid Tissue 위 림프종 2예
최보광 ( Bo Gwang Choi ),김광하 ( Gwang Ha Kim ),이정남 ( Jung Nam Lee ),박성한 ( Sung Han Park ),이봉은 ( Bong Eun Lee ),류동엽 ( Dong Yup Ryu ),송근암 ( Geun Am Song ),박도윤 ( Do Youn Park ) 대한소화기학회 2010 대한소화기학회지 Vol.56 No.2
Gastric mucosa-associated lymphoid tissue (MALT) lymphoma is the most common form of primary extranodal lymphomas. In most cases, it is developed as multifocal and mucosal lesions, and its initial diagnosis is made by biopsy of suspicious lesions on endoscopy. However, when gastric MALT lymphoma afflict submucosal site without typical mucosal lesion, further procedures are necessary for diagnosis, such as endoscopic mucosal resection and endoscopic ultrasonography. We recently experienced two cases of submucosal tumor-like gastric MALT lymphoma. Both cases were without any mucosal lesion. One case was confirmed by endoscopic mucosal resection, and the latter was by wedge resection. Treatment modalities included endoscopic mucosal resection, surgery, H. pylori eradication, and/or chemotherapy. Both cases achieved complete remission until our 18 months` and 16 months` follow up. (Korean J Gastroenterol 2010;56:103-108)
( In Hye Hwang ),( Joo Seop Chung ),( Ho Jin Shin ),( Young Jin Choi ),( Moo Kon Song ),( Young Mi Seol ),( Goon Jae Cho ),( Bo Gwang Choi ),( Mun Ki Choi ),( Bo Kyung Choi ),( Kang Hee Ahn ),( Kyung 대한내과학회 2011 The Korean Journal of Internal Medicine Vol.26 No.1
Background/Aims: Autologous stem cell transplantation (ASCT) has become the treatment of choice for patients with multiple myeloma (MM). Studies have shown that maintenance treatment with interferon-alpha is associated with improved survival rates following ASCT. However, despite these recent advances in regimes, relapses are inevitable; thus, the prediction of relapse following ASCT requires assessment. Methods: We retrospectively analyzed 39 patients who received ASCT between 2003 and 2008. All patients received chemotherapy with vincristine, adriamycin, and dexamethasone (VAD), and ASCT was performed following high-dose melphalan conditioning therapy. We evaluated the influence of the post-transplant day +14 (D+14) bone marrow plasma cell percent (BMPCp) (≥ 2 vs. < 2%), international scoring system (ISS) stage (II vs. III), response after 3 cycles of VAD therapy (complete response [CR] vs. non-CR), deletion of chromosome 13q (del[13q]) (presence of the abnormality vs. absence), and BMPCp at diagnosis (≥ 50 vs. < 50%) on progressionfree survival (PFS) and overall survival (OS). Results: During the median follow-up of 28.0 months, the median PFS and OS were 29.1 and 42.1 months, respectively. By univariate analysis, ISS stage III at diagnosis, BMPCp ≥ 50% at diagnosis, CR after 3 cycles of VAD therapy, del (13q) by fluorescence in situ hybridization, and BMPCp ≥ 2% at post-transplant D+14 were correlated with PFS and OS. A multivariate analysis revealed that a post-transplant D+14 BMPCp ≥ 2% (PFS, hazard ratio [HR] = 4.426, p = 0.008; OS, HR = 3.545, p = 0.038) and CR after 3 cycles of VAD therapy (PFS, HR = 0.072, p = 0.014; OS, HR = 0.055, p = 0.015) were independent prognostic parameters. Conclusions: Post-transplant D+14 BMPCp is a useful parameter for predicting the outcome for patients with MM receiving ASCT. (Korean J Intern Med 2011;26:76-81)
Hwang, In Hye,Chung, Joo Seop,Shin, Ho Jin,Choi, Young Jin,Song, Moo Kon,Seol, Young Mi,Cho, Goon Jae,Choi, Bo Gwang,Choi, Mun Ki,Choi, Bo Kyung,Ahn, Kang Hee,Shin, Kyung Hwa,Lee, Hee Sun,Nam, Hyung S The Korean Association of Internal Medicine 2011 The Korean Journal of Internal Medicine Vol.26 No.1
<P><B>Background/Aims</B></P><P>Autologous stem cell transplantation (ASCT) has become the treatment of choice for patients with multiple myeloma (MM). Studies have shown that maintenance treatment with interferon-alpha is associated with improved survival rates following ASCT. However, despite these recent advances in regimes, relapses are inevitable; thus, the prediction of relapse following ASCT requires assessment.</P><P><B>Methods</B></P><P>We retrospectively analyzed 39 patients who received ASCT between 2003 and 2008. All patients received chemotherapy with vincristine, adriamycin, and dexamethasone (VAD), and ASCT was performed following high-dose melphalan conditioning therapy. We evaluated the influence of the post-transplant day +14 (D+14) bone marrow plasma cell percent (BMPCp) (≥ 2 vs. < 2%), international scoring system (ISS) stage (II vs. III), response after 3 cycles of VAD therapy (complete response [CR] vs. non-CR), deletion of chromosome 13q (del[13q]) (presence of the abnormality vs. absence), and BMPCp at diagnosis (≥ 50 vs. < 50%) on progression-free survival (PFS) and overall survival (OS).</P><P><B>Results</B></P><P>During the median follow-up of 28.0 months, the median PFS and OS were 29.1 and 42.1 months, respectively. By univariate analysis, ISS stage III at diagnosis, BMPCp ≥ 50% at diagnosis, CR after 3 cycles of VAD therapy, del (13q) by fluorescence <I>in situ</I> hybridization, and BMPCp ≥ 2% at post-transplant D+14 were correlated with PFS and OS. A multivariate analysis revealed that a post-transplant D+14 BMPCp ≥ 2% (PFS, hazard ratio [HR] = 4.426, <I>p</I> = 0.008; OS, HR = 3.545, <I>p</I> = 0.038) and CR after 3 cycles of VAD therapy (PFS, HR = 0.072, <I>p</I> = 0.014; OS, HR = 0.055, <I>p</I> = 0.015) were independent prognostic parameters.</P><P><B>Conclusions</B></P><P>Post-transplant D+14 BMPCp is a useful parameter for predicting the outcome for patients with MM receiving ASCT.</P>
Necrophagous insect fauna on carcasses relative to the decomposition stages in Daejeon area
Bo-Yeon Choi,Seol-Hui Ko,So-Yeon Lim,Young-Gwang Song,Kyeong-Won Lee,Bong-Kyu Byun 한국응용곤충학회 2023 한국응용곤충학회 학술대회논문집 Vol.2023 No.10
닭 사체를 이용하여 장소, 기온, 습도별 시식성 곤충상을 파악하기 위해 대전광역시 전민동 일대의 3개의 장소 를 선택하여 닭 사체별로 유인되는 곤충의 종류와 군집 상의 차이와 출현양상을 조사하였다. 이를 위해, 닭 사체에 유인되는 곤충을 주기적으로 채집하고 해당 일자의 온도와 습도를 조사하여 기록했으며, 채집한 곤충들은 외부 형태적 특징으로 분류하고 개체수를 확인했다. 조사결과, 딱정벌레목과 파리목의 개체가 가장 많았고, 그 외에 바퀴목, 벌목, 노린재목 분류군에 속하는 다양한 곤충들이 유인된 것을 확인할 수 있었다. 본 연구 결과는 법곤충 시식성 곤충을 연구하는데 중요한 기초자료로 활용될 수 있도록 결과를 종합정리하였다.
Case Reports : A Case of Cicatricial Alopecia Associated with Erlotinib
( Bo Hee Yang ),( Chan Yl Bang ),( Ji Won Byun ),( Sung Hyub Han ),( Hee Jin Song ),( Seung Gyun In ),( Jeong Hyun Shin ),( Gwang Seong Choi ) 대한피부과학회 2011 Annals of Dermatology Vol.23 No.3s
Erlotinib is a small-molecule tyrosine kinase inhibitor (TKI) of the epidermal growth factor receptor (EGFR). Erlotinib has been used primarily to treat non-small cell lung cancer. In addition to its role in tumor cells, EGFR is also an important regulator of growth and differentiation in the skin and hair. Therefore, EGFR-TKIs have been associated with a number of cutaneous side effects including follicular acneiform eruptions, cutaneous xerosis, chronic paronychia, desquamation, seborrheic dermatitis, and hair texture changes. Herein, we report a rare case of a 61-year-old woman who was treated with erlotinib and experienced cicatricial alopecia. (Ann Dermatol 23(S3) S350~S353, 2011)
A Case of Cicatricial Alopecia Associated with Erlotinib
Yang, Bo Hee,Bang, Chan Yl,Byun, Ji Won,Han, Sung Hyub,Song, Hee Jin,In, Seung Gyun,Shin, Jeong Hyun,Choi, Gwang Seong Korean Dermatological Association; The Korean Soci 2011 Annals of Dermatology Vol.23 No.suppl3
<P>Erlotinib is a small-molecule tyrosine kinase inhibitor (TKI) of the epidermal growth factor receptor (EGFR). Erlotinib has been used primarily to treat non-small cell lung cancer. In addition to its role in tumor cells, EGFR is also an important regulator of growth and differentiation in the skin and hair. Therefore, EGFR-TKIs have been associated with a number of cutaneous side effects including follicular acneiform eruptions, cutaneous xerosis, chronic paronychia, desquamation, seborrheic dermatitis, and hair texture changes. Herein, we report a rare case of a 61-year-old woman who was treated with erlotinib and experienced cicatricial alopecia.</P>
Irbesartan prevents myocardial remodeling in experimental thyrotoxic cardiomyopathy.
Kim, Bo Hyun,Cho, Kyoung Im,Kim, Seong Man,Kim, Jee-Yeon,Choi, Bo Gwang,Kang, Ji Hyun,Jeon, Yun Kyung,Kim, Sang Soo,Kim, Seong-Jang,Kim, Yong Ki,Kim, In Joo Japan Endocrine Society 2012 Endocrine journal Vol.59 No.10
<P>This study evaluated the effects of irbesartan and propranolol on thyroid hormone (TH)-induced cardiac functional and structural remodeling. A rat model of thyrotoxicosis was established by daily intraperitoneal injections of L-thyroxine (T(4), 100 μg/kg) for 4 weeks. Forty Sprague-Dawley rats were randomly divided into four groups (n = 10 each): control group, T(4) group (T(4) alone), T(4) plus irbesartan group (T(4)-Irb, 30 mg/kg), and T(4) plus propranolol group (T(4)-Pro, 0.5mg/mL of drinking water). Cardiac chamber size and functional parameters were measured by echocardiography and cardiomyocyte diameter. Heart rate (HR) and cardiac fibrosis were determined. T(4) alone showed significantly increased HR and cardiomyocyte width (25.0 1.77 vs. 18.8 0.84 μm, P < 0.001) with fibrosis, reduced left ventricle (LV) longitudinal strain (S(long); -16.0 6.27 vs. -22.7 5.19 %, P < 0.001) compared with control. When compared with T(4) alone, T(4)-Irb showed significantly improved LV S(long) (-21.4 1.84 vs. -16.0 6.27 %, P =0.017) and reduced cardiomyocyte width (21.0 1.0 vs. 25.0 1.77 μm, P =0.002) with comparable HR (458.4 24.3 vs. 486.6 30.1 bpm, P = 0.086). However, T(4)-Pro showed significantly reduced HR with improved LV S(long) without alteration of cardiomyocyte width and fibrosis compared with T(4) alone. In conclusion, renin-angiotensin system (RAS) blocking by irbesartan could significantly attenuate TH-induced cardiac structural and functional remodeling. However, HR reduction by propranolol could not alternate structural remodeling, which may implicate the RAS as having an important role in thyrotoxic cardiomyopathy beyond tachycardia.</P>